The COMPASS trial (NCT01776424) compared outcomes of subjects with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) taking rivaroxaban plus aspirin with subjects taking aspirin alone. The primary outcome (a composite of myocardial infarction, stroke, or cardiovascular [CV] death) was decreased by 24% in the group taking rivaroxaban plus aspirin. … [Read more...] about Rivaroxaban plus aspirin confers mortality benefit over aspirin alone
Cardiology research news
Lowering target systolic blood pressure may decrease cardiovascular events
International Society of Hypertension global hypertension guidelines1 and European Society of Cardiology guidelines2 both recommend that hypertension be diagnosed if a patient’s systolic blood pressure is ≥140 mmHg and/or their diastolic blood pressure is ≥90 mmHg. Researchers wondered if pharmaceutical intervention at a lower systolic blood pressure could further reduce the … [Read more...] about Lowering target systolic blood pressure may decrease cardiovascular events
Fractional flow reserve vs angiography-guided revascularization
Fractional flow reserve (FFR) guided revascularization did not demonstrate any benefit over angiography guided revascularization in the FLOWER-MI trial. In patients with ST-elevated myocardial infarction (STEMI) and multi-vessel disease, complete vascularization is associated with better clinical outcomes than vascularization of only the culprit lesion. Current … [Read more...] about Fractional flow reserve vs angiography-guided revascularization
Clopidogrel monotherapy superior to aspirin monotherapy following PCI
In the HOST-EXAM trial investigators found monotherapy with clopidogrel (in patients who had experienced an event-free 6 to 18 months) following percutaneous coronary intervention (PCI; using a drug-eluting stent) was superior to monotherapy with aspirin, over a 2-year follow-up period. Clopidogrel was associated with both fewer thrombotic and bleeding endpoints. In … [Read more...] about Clopidogrel monotherapy superior to aspirin monotherapy following PCI
Top 10 Highlights of ESC Congress 2021
The European Society of Cardiology (ESC) 2021 occurred virtually this year from 27-30 August. Here is our curated list of the top 10 highlights of ESC 2021. EMPEROR-Preserved trial1 (NCT03057951): This phase 3 trial randomized 5988 adults with chronic heart failure (HF) with preserved ejection fraction (HFpEF) to take either sodium-glucose cotransporter 2 inhibitor … [Read more...] about Top 10 Highlights of ESC Congress 2021